# Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery

> **NCT00833859** · PHASE2 · TERMINATED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 2 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** GTX (gemcitabine, docetaxel and capecitabine)
- **RADIATION:** stereotactic body radiation therapy

## Key facts

- **NCT ID:** NCT00833859
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Abandoned - Lack of funding after only 2 patients enrolled
- **Last updated:** 2017-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833859, "Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT00833859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*